Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase 3 (P3) global studies of up to 24 months’ duration were evaluated. METHODS: Data were pooled from Brazilian p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Lomonte, Andrea B.V., Radominski, Sebastião C., Marcolino, Flora M.D., Brenol, Claiton V., Zerbini, Cristiano A.F., García, Erika G., Akylbekova, Ermeg L., Rojo, Ricardo, de Leon, Dario Ponce
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6081087/
https://ncbi.nlm.nih.gov/pubmed/30075534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011609
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados